(Q46495851)

English

Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR.

scientific article published on 17 May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Edward D Frohlich

4

object named as

Edward D Frohlich

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

author name string

Xiaoyan Zhou

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Luis C Matavelli

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Hidehiko Ono

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

publication date

17 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

American Journal of Physiology - Renal Physiology

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

289

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

F871-9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Combination of low-dose valsartan and enalapril improves endothelial dysfunction and coronary reserve in Nomega-nitro-L-arginine methyl ester-treated spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Bradykinin-mediated effects of ACE inhibition.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH).

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Dual renin-angiotensin system blockade at optimal doses for proteinuria

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Apoptosis and glomerular injury after prolonged nitric oxide synthase inhibition in spontaneously hypertensive rats.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Nitric oxide synthase inhibition in a spontaneously hypertensive rat model of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Differential effects of antihypertensive drugs on renal and glomerular hemodynamics and injury in the chronic nitric-oxide-suppressed rat.

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00129.2005

21 January 2018

Identifiers

10.1152/AJPRENAL.00129.2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15900021

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46495851&oldid=1404894977"